Purchase this article with an account.
E. Ryu, R. Jun; Evaluation of in vitro Effects of Bevacizumab on Cultured Bovine Corneal Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3947.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the in vitro effects of bevacizumab (Avastin®, Genentech, Inc., CA) on cultured bovine corneal endothelial cells (BCE C/D-1b).
Cultured BCE C/D-1b cells were treated with 6.25 mg/mL, 3.125 mg/mL, 1.25 mg/mL, 0.625 mg/ml, and 0.3125 mg/mL of bevacizumab for 2, 6, and 24 hours. Cell viability was measured with hemocytometer and it was compared with the control group. We observed the structural change of the cells with light microscope and transmission electron microscope.
The cell viabilities of BCE C/D-1b cells treated with bevacizumab for 2 and 6 hours were not significantly different from that of untreated controls (p>0.05). However the cells treated with 6.25 mg/mL, 3.125 mg/mL and 1.25 mg/mL of bevacizumab for 24 hours showed significantly decreased cell viability compared to the control. On light microscope, these groups appeared more intracellular vaculoles and some deposits. Dead or dying cells were of various size, had bizarre shape and irregular morphology. On transmission electron microscope, marked intracellular vacuoles, disrupted cell membranes were observed. The surface microvillus were deformed and intracellular organelles were swollen.
This study suggests that bevacizumab, at concentration above the normally used in clinical practice, is toxic to BCE C/D-1b cells in vitro.
This PDF is available to Subscribers Only